Document is current
Any future updates will be listed below
-
Authors
Katsarova–Harrison, Stanislava
Whelehan, Gráinne
Henson, Joseph
Herring, Louisa Y.
Bowrey, David
Thackray, Alice E.
Stensel, David J.
Idris, Iskander
Anyiam, Oluwaseun
Zalin, Anjali
Askari, Alan
Webb, David R.
Yates, Tom
Davies, Melanie J.
Papamargaritis, Dimitris
-
Funding
Funding for this research was provided by:
Novo Nordisk UK Research Foundation and the Leicester NIHR BRC
- License Information
-
More Information
Article History
Received: 26 September 2025
Revised: 29 October 2025
Accepted: 24 November 2025
First Online: 28 November 2025
Declarations
:
: Ethical approval for the study was granted by the Yorkshire & Humber South Yorkshire Research Ethics Committee (20/YH/0177). The study was registered in the ISRCTN registry (ISRCTN12008159). All study procedures were carried out in accordance with good clinical practice guidelines and the Declaration of Helsinki (1964).
: All participants provided written informed consent prior to being enrolled onto the study.
: DP has acted as a speaker for Novo Nordisk, Eli Lilly, Boehringer Ingelheim and Johnson and Johnson and has received grants from Novo Nordisk, Novo Nordisk UK Research Foundation, Academy of Medical Sciences/Diabetes UK, Health Education East Midlands and the National Institute for Health and Care Research (NIHR). II has received research grant or speaker fees for: Eli Lilly, Novo Nordisk, Boehringer, Sanofi, Astra Zenica. MJD has acted as a consultant/advisor and speaker for Eli Lilly, Novo Nordisk and Sanofi, has attended advisory boards for AbbVie, Amgen, AstraZeneca, Biomea Fusion, Carmot/Roche, Sanofi, Zealand Pharma, Regeneron, GSK and EktaH and as a speaker for AstraZeneca and Boehringer Ingelheim and has received grants from AstraZeneca, Boehringer Ingelheim and Novo Nordisk.
